ARPLA: a revolutionary glycoRNA imaging tool with precision and power

Background/problem 

Glycosylated RNAs (GlycoRNAs) are a newly discovered class of molecules involved in glycosylation. They have been found on the surfaces of various cell types, organisms, and species, further advancing the role of RNA in biological processes. Despite this, our knowledge of glycoRNAs and their functions remains limited, primarily due to the lack of effective methods to visualize and study these molecules in living organisms. Existing methods (such as RNA blotting, NGS, HPLC, and MS) have limitations in specificity, spatial resolution, or direct visualization on cell surfaces.

Technology overview/solution

UT Austin researchers have designed a novel method called Sialic Acid Aptamer and RNA in situ Hybridization-mediated Proximity Ligation Assay (ARPLA). This patent-pending method will directly visualize glycoRNAs on the cell surface with high sensitivity and selectivity, while also providing both sequence and spatial information, unlike current methods.

ARPLA utilizes a dual-probe system: a sialic acid aptamer (single-stranded nucleic acids that act as affinity reagent) for glycan-binding and an RNA hybridization probe to target the RNA part of the glycoRNA. The key to ARPLA is the in-situ proximity ligation assay, which requires that these two probes be close to each other to generate a signal. This dual recognition-in-proximity prevents false positive signals.

Benefits/competitive advantage

ARPLA’s high sensitivity, selectivity, and its ability to image unlabeled glycoRNAs make it a powerful tool for investigating the roles of glycoRNAs in many biological processes and uncovering their relevance to diseases. It offers several competitive advantages:

  • Efficiency: ARPLA is faster than metabolic labeling and RNA blot.
  • Versatility: It can visualize native, unlabeled glycoRNAs in various types of samples without the need for metabolic labeling used in RNA blot.
  • High sensitivity: One-of-a-kind method that can provide spatial distribution of glycoRNAs with high sensitivity
  • High specificity: ARPLA can achieve significantly high specificity for glycoRNA, avoiding false positives.
  • Customizability: ARPLA can be tailored for specific glycoRNA sequences.

ARPLA has shown promise in breast cancer research, immune cell differentiation, and response to lipopolysaccharide (LPS) stimulation.

Opportunity

  • Research advancement: ARPLA represents a significant advancement in glycoRNA research, enhancing our understanding of its functions, interactions, and relevance to diseases.
  • Drug discovery: Provides novel opportunities for drug discovery by identifying new drug targets associated with glycoRNA, potentially revolutionizing treatment strategies.
  • Diagnostic innovation: Offers a promising avenue for disease diagnostics, leveraging glycoRNA profiles as biomarkers for early detection and personalized medicine.
  • Biotechnological applications: Holds potential applications in biotechnology, supporting the development of innovative healthcare solutions tailored to individual patient needs.
  • Market growth potential: Positioned within the expanding RNA therapeutics market, which is projected to grow substantially from $13.9 billion in 2023 to $22.32 billion by 2032, reflecting a CAGR of 6.10%.
Patent Information: